VISEN Pharmaceuticals Concludes Stabilization Period and Confirms Compliance

VISEN Pharmaceuticals ( (HK:2561) ) has provided an announcement.

VISEN Pharmaceuticals announced the conclusion of the stabilization period for its Global Offering, which ended on April 17, 2025. During this period, stabilizing actions were undertaken, including the over-allocation and purchase of shares by Morgan Stanley Asia Limited. The Over-allotment Option was not exercised and has lapsed, meaning no additional shares will be issued. The company confirms compliance with public float requirements, maintaining its market positioning and regulatory adherence.

More about VISEN Pharmaceuticals

VISEN Pharmaceuticals is a company incorporated in the Cayman Islands, operating within the pharmaceutical industry. The company focuses on developing and offering pharmaceutical products, with a market emphasis on global offerings and public share trading.

YTD Price Performance: -39.68%

Average Trading Volume: 420,207

See more insights into 2561 stock on TipRanks’ Stock Analysis page.